Physician profile
Tom Ku
NPI 1609955285
$16,003.81
in general payments reported to CMS, 2019-2025
45 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,627 · 2022: $3,289 · 2023: $2,488 · 2024: $2,948 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,088.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,260.62 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $2,602.59 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,959.68 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,768.75 | 2021 | |
| Abbvie INC. | $1,466.70 | 2021-2025 | |
| Pfizer INC. | $624.43 | 2021-2025 | |
| Glaxosmithkline, LLC. | $604.13 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $600.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $409.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.90 | 2022-2024 | Jardiance, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $225.94 | 2021-2025 | |
| Abbott Laboratories | $218.61 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.22 | 2021-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $174.61 | 2021-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $174.05 | 2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $146.67 | 2021 | |
| Merck Sharp & Dohme LLC | $137.10 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $135.43 | 2022 | |
| Almatica Pharma LLC | $118.31 | 2024-2025 | Loreev Xr, Teriparatide |
| Antares Pharma, INC. | $80.14 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $74.56 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $73.02 | 2024-2025 | Tlando |
| Astellas Pharma US INC | $68.14 | 2024 | Veozah |
| Eisai INC. | $54.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.46 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $46.36 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $44.70 | 2022-2025 | Recorlev |
| Bausch Health US, LLC | $40.66 | 2021-2022 | |
| Smith+Nephew, INC. | $37.93 | 2023 | Grafix |
| Axsome Therapeutics, INC. | $37.44 | 2025 | Symbravo |
| Cvrx, INC. | $31.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.93 | 2021-2022 | |
| Dexcom, INC. | $24.99 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $22.36 | 2023 | Mazor X System |
| Si-Bone, INC. | $21.91 | 2022 | |
| Hologic Sales and Service, LLC | $21.62 | 2024 | Thinprep 2000 Processor, Aptima |
| Mylan Specialty L.P. | $20.68 | 2022 | |
| Edwards Lifesciences Corporation | $19.04 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Arbor Pharmaceuticals, INC. | $18.57 | 2021 | |
| Halozyme INC | $17.86 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2025 | Zoryve |
| Impel Pharmaceuticals INC. | $15.60 | 2022 | |
| Tolmar, INC. | $14.62 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2022 | |
| Intra-Sana Laboratories | $13.47 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Ku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.